- Home
- EQH vs VANI Comparison
EQH vs VANI Comparison
Compare EQH & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQH
- VANI
- Stock Information
- Founded
- EQH 1859
- VANI 1998
- Country
- EQH United States
- VANI United States
- Employees
- EQH N/A
- VANI N/A
- Industry
- EQH Specialty Insurers
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- EQH Finance
- VANI Health Care
- Exchange
- EQH Nasdaq
- VANI Nasdaq
- Market Cap
- EQH N/A
- VANI 68.1M
- IPO Year
- EQH N/A
- VANI 2014
- Fundamental
- Price
- EQH $55.67
- VANI $1.26
- Analyst Decision
- EQH Strong Buy
- VANI Strong Buy
- Analyst Count
- EQH 11
- VANI 1
- Target Price
- EQH $62.45
- VANI $4.00
- AVG Volume (30 Days)
- EQH 2.7M
- VANI 146.6K
- Earning Date
- EQH 07-29-2025
- VANI 08-12-2025
- Dividend Yield
- EQH 1.94%
- VANI N/A
- EPS Growth
- EQH 13.70
- VANI N/A
- EPS
- EQH 3.76
- VANI N/A
- Revenue
- EQH $15,105,000,000.00
- VANI N/A
- Revenue This Year
- EQH $22.89
- VANI N/A
- Revenue Next Year
- EQH $3.86
- VANI N/A
- P/E Ratio
- EQH $14.81
- VANI N/A
- Revenue Growth
- EQH 45.39
- VANI N/A
- 52 Week Low
- EQH $36.46
- VANI $0.91
- 52 Week High
- EQH $56.61
- VANI $1.50
- Technical
- Relative Strength Index (RSI)
- EQH 60.35
- VANI 58.97
- Support Level
- EQH $55.40
- VANI $1.24
- Resistance Level
- EQH $56.61
- VANI $1.33
- Average True Range (ATR)
- EQH 1.18
- VANI 0.06
- MACD
- EQH 0.17
- VANI 0.00
- Stochastic Oscillator
- EQH 81.75
- VANI 59.09
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.